# Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg

> **NCT06331715** · PHASE4 · COMPLETED · sponsor: **Megalabs** · enrollment: 24 (actual)

## Conditions studied

- Bioequivalence

## Interventions

- **DRUG:** Palbociclib 125mg

## Key facts

- **NCT ID:** NCT06331715
- **Lead sponsor:** Megalabs
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-06
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-05-31
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06331715

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06331715, "Bioequivalence Study of Palbociclib 125 mg Capsules of Iclos vs. Ibrance (Palbociclib) Capsules 125 mg". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06331715. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*